Retrospective chart review on natalizumab: Efficacy and safety of long-term treatment with natalizumab in Japanese patients with RRMS

Retrospective chart review on natalizumab: Efficacy and safety of long-term treatment with natalizumab in Japanese patients with RRMS - Retrospective chart review on long-term treatment with natalizumab in Japanese patients with RRMS

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000033924

Enrollment

Registered

2018-08-28

Start date

2018-08-28

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsing-Remitting Multiple Sclerosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Relapsing-Remitting Multiple Sclerosis 2. 18 years old or over 3.Treated for at least 1 year with natalizumab (including patients who discontinued after receiving natalizumab for more than 1 year). 4. No treatment gap of more than 12 weeks

Exclusion criteria

Exclusion criteria: Refusal of consent by opt-out prior to the initiation of the study

Design outcomes

Primary

Measure	Time frame
The proportion of subjects with new/newly enlarging T2-hyperintense lesions after treatment (each year up to 5 years)	—

Secondary

Measure	Time frame
The changes after treatment (each year up to 5 years) in the following: - Proportion of subjects with new Gd-enhancing lesions - Clinical relapse rate (ARR) - Expanded disability status scale - Anti-JCV antibody index	—

Countries

Japan

Contacts

Public ContactTakahiko Saida

IRINO MEDICAL CLINIC, LLC Neurology

saida_takahiko@icloud.com090-2287-1021

Outcome results